Literature DB >> 2673968

Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis.

D J Mutimer1, S P Fussey, S J Yeaman, P J Kelly, O F James, M F Bassendine.   

Abstract

We have previously identified four of the M2 antigens in primary biliary cirrhosis as the E2 components (dihydrolipoamide acyltransferases) of pyruvate dehydrogenase complex, branched-chain 2-oxo acid dehydrogenase complex and 2-oxoglutarate dehydrogenase complex and the protein X component of pyruvate dehydrogenase complex (approximate molecular masses: 74, 50, 50 and 52 kD, respectively). In the present study, we have examined by immunoblotting the frequency of IgG and IgM autoantibodies to these four proteins in 129 patients with primary biliary cirrhosis (36 histological Stage I, 42 Stage II/III, 51 Stage IV) and 77 controls (49 non-primary biliary cirrhosis chronic liver disease, 16 primary Sjögren's syndrome, 12 healthy normal women). One hundred twenty-seven of 129 (98%) primary biliary cirrhosis patients had antibodies against at least one of the four M2 polypeptides, compared to 2/77 controls (both had autoimmune chronic active hepatitis and were antimitochondrial antibody positive by indirect immunofluorescence). One hundred twenty-one of 129 (94%) primary biliary cirrhosis sera reacted with the E2 component and protein X of pyruvate dehydrogenase complex, 69/129 (53%) primary biliary cirrhosis sera reacted with E2 of branched-chain 2-oxo acid dehydrogenase complex and 113/129 (88%) reacted with E2 of 2-oxoglutarate dehydrogenase complex. Primary biliary cirrhosis patients with histological Stage I disease had a lower incidence of autoantibodies to each M2 protein, compared to more advanced disease (IgG, p less than 0.05) but only 2/36 Stage I patients had no anti-M2 antibodies. There was no correlation between the presence of IgG or IgM antibodies to the M2 polypeptides and established prognostic markers in primary biliary cirrhosis (serum bilirubin and albumin levels).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2673968     DOI: 10.1002/hep.1840100402

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  16 in total

Review 1.  Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis.

Authors:  Tin K Mao; Paul A Davis; Joseph A Odin; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

Review 2.  Primary biliary cirrhosis: nature of autoantigens.

Authors:  M F Bassendine; S J Yeaman
Journal:  Springer Semin Immunopathol       Date:  1990

Review 3.  Mitochondrial antigens and antibodies in primary biliary cirrhosis.

Authors:  P Butler; F Valle; A K Burroughs
Journal:  Postgrad Med J       Date:  1991-09       Impact factor: 2.401

4.  Plasma membrane association of primary biliary cirrhosis mitochondrial marker antigen M2.

Authors:  U Sundin; K G Sundqvist
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  Autoimmune cholangitis.

Authors:  J Heathcote
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

6.  Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models.

Authors:  R Jalan; J Sargentoni; G A Coutts; J D Bell; K Rolles; A K Burroughs; S D Taylor Robinson
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 7.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 8.  Autoantigens in primary biliary cirrhosis.

Authors:  D E Jones
Journal:  J Clin Pathol       Date:  2000-11       Impact factor: 3.411

Review 9.  The diagnosis of primary biliary cirrhosis.

Authors:  Christopher L Bowlus; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

Review 10.  [Autoimmune liver diseases].

Authors:  S Lüth; C Weiler-Normann; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.